New therapeutic approach for treating MASLD/MASH
CMR CureDiab Metabolic Research GmbH
CureDiab high-tech start-up: Our vision
CMR CureDiab Metabolic Research GmbH is a recently established high-tech start-up in the seed phase. As a spin-off from the German Diabetes Center, CureDiab operates high-tech labs integrated in the infrastructure of the center. The vision of the company is to establish a new therapeutic approach for treating MASLD/MASH based on activation of the GABA-A ion channel. Corresponding patent applications have been filed.
Our lead compound targets key mechanisms of metabolic liver disease—offering a novel multi-pathway approach to treat MASH at its roots.
We combine deep biological insight with cutting-edge research—from molecular signaling to organ-level effects—to develop therapies with lasting impact.
With a clear path from preclinical to clinical development, CureDiab is set to bring first-in-class treatments to patients with high unmet medical need.
Metabolic dysfunction–associated steatotic liver disease
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a common and progressive liver condition driven by metabolic risk factors such as obesity and type 2 diabetes. It begins with the accumulation of fat in the liver (steatosis) and can progress to metabolic dysfunction-associated steatohepatitis (MASH), a more severe stage marked by inflammation and liver cell damage. If left untreated, MASH can lead to fibrosis, cirrhosis, liver failure, or even liver cancer. Despite its rising global prevalence, effective therapeutic options remain limited, making MASLD one of the most urgent unmet needs in modern medicine.
CureDiab develops a novel first-in-class approach for steatotic liver
© 2022 cureDiab All rights reserved